Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands
Executive Summary
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
You may also be interested in...
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.
Moving The Needle In Rare Disease: UCB’s gMG Strategy
Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.
Win Big Or Lose Big: The Impact Of The Unified Patent Court
Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?